Home
EN / FR

Celyad Oncology

Home / Investors / Regulated Information

Regulated Information

Financial Reports

25

Mar
2021

Full Year 2020 Annual Report & Business Highlights

EN

FR

31

Mar
2021

Annual Report 2020

FR

EN

06

May
2021

First Quarter 2021 Financial Results and Recent Business Highlights

EN

FR

22

Mar
2020

Full Year 2019 Annual Report

EN

FR

02

Apr
2020

Annual Report 2019

EN

FR

07

May
2020

First Quarter 2020 Financial Results and Recent Business Highlights

EN

FR

06

Aug
2020

Half Year 2020 Financial Results and Business Highlights

EN

FR

10

Nov
2020

Third Quarter 2020 Financial Results and Recent Business Highlights

FR

EN

28

Mar
2019

Full Year 2018 Financial and Operating Results

EN

FR

05

Apr
2019

Annual Report 2018

EN

FR

09

May
2019

First Quarter 2019 Financial Results and Recent Business Highlights

EN

FR

22

Aug
2019

Interim Financial Report H1.2019

EN

FR

19

Nov
2019

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

EN

FR

22

Mar
2018

Full year 2017 Financial and Operating Results

EN

FR

06

Apr
2018

Annual report 2017

EN

FR

15

May
2018

First Quarter 2018 Financial Results and Recent Business Highlights

EN

FR

23

Aug
2018

First Half 2018 Financial Results and Operational Progress

EN

FR

21

Nov
2018

Third Quarter 2018 Business Update

EN

FR

23

Mar
2017

Celyad Reports 2016 Financial and Operating Results

EN

FR

19

May
2017

First Quarter 2017 Business Update

EN

FR

26

May
2017

Celyad’s Annual Report 2016

EN

FR

29

Aug
2017

First Half 2017 Financial statements and operational progress

EN

FR

06

Apr
2016

AR 2015 Annual report

EN

20

May
2016

Q1 2016 Business Update

EN

25

Aug
2016

Celyad 2016 First Half Year Report

EN

FR

18

Nov
2016

Q3 2016 Business Update

EN

FR

30

Jun
2015

H1 2015 Interim Financial Report

EN

FR

19

Nov
2015

Q3 2015 Business Update

EN

FR

SEC Filings

Filter

Filing Date
Form
Description
Filing Group
Downloads
June 11, 2021

6-K

Celyad Oncology Presents Preliminary Data From Phase 1 IMMUNICY-1 Trial Of ShRNA-Based Allogeneic CAR T Candidate CYAD-211 In r/r MM At The EHA Virtual Congress

May 12, 2021

6-K

Report of Foreign Issuer

Current reports

May 7, 2021

6-K

Report of Foreign Issuer

Current reports

March 25, 2021

20-F

Annual and Transition Report (foreign private issuer)

Other

February 2, 2021

SC 13G/A

Celyad Oncology Filed by Victory Capital Management INC

January 20, 2021

6-K

Report of foreign issuer

Current reports

Regulated Information

Filter

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Press Releases | June 11th, 2021

Read More

Summary Note – FR

Uncategorized | June 9th, 2021

Read More

Summary Note – EN

Uncategorized | June 9th, 2021

Read More
Load More